A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Exclusion Criteria

• •History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in study eye
• •Previous subfoveal focal laser photocoagulation in study eye
• •Laser photocoagulation in the study eye
• •Prior treatment with external-beam radiation therapy or transpupillary thermotherapy in study eye
• •Previous intravitreal drug administration in study eye. A single intraoperative administration of a corticosteroid during cataract surgery at least 3 months prior to screening is permitted
• •Previous cell-based intraocular treatment in study eye
• •Intraocular surgery in study eye
• •Uncontrolled glaucoma and history of glaucoma-filtering surgery in study eye
• •History of corneal transplant in study eye
• •GA in either eye due to causes other than AMD
• •Proliferative diabetic retinopathy in either eye
• •Active or history of neovascular (wet) AMD in either eye
• •History of idiopathic or autoimmune-associated uveitis, ocular or intraocular conditions, and infectious or inflammatory ocular disease
• •Active uveitis and infectious conjunctivitis, keratitis, scleritis or endophthalmitis
• •Previous systemic treatment with complement inhibitor and with inhibitors/modulators of visual cycle
• •Previous expression vector mediated intraocular treatments
• •Uncontrolled blood pressure and atrial fibrillation
• •Medical conditions associated with clinically significant risk for bleeding-
• •Predisposition or history of increased risk for infection
• •Active malignancy within the previous 12 months except for appropriately treated carcinoma in situ of cervix, resolved non-melanoma skin carcinoma, and prostate cancer with a Gleason score of less than or equal to 6, and a stable prostate-specific antigen for greater than or equal to (\>/=) 12 months
• •History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of lampalizumab injection
• •Women of child bearing potential must have a negative serum pregnancy test within 28 days prior to initiation of study treatment
• •Previous participation in other studies of investigational drugs